Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A
Repligen Corporation announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world’s approved monoclonal antibodies. The patent, which will remain …

Read more on News-Medical-Net

Related posts:

1. How does protein synthesis process effect the distribution of hypocretin protein in narcolepsy people?
2. Browse News
3. B Street Theatre’s ‘Conductor’ delivers a vital chapter of freedom
4. Targeting brain circuits for addiction, relapse
5. People With No Health Insurance Get Substandard Migraine Care